Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women.
Baseline serum samples from 2815 human immunodeficiency virus (HIV)-positive and 963 HIV-negative women enrolled in 2 cohort studies were tested for immunoglobulin G antibodies to human papillomavirus type 16 (HPV-16) capsids. HPV-16 seropositivity was associated with lifetime number of sex partners (P<.001) among both HIV-positive and HIV-negative women. Approximately 50%-60% of HPV-16 DNA-positive women were HPV-16 positive. HPV-16 seropositivity was associated with HIV infection; however, after adjustment for baseline cervical HPV infection and disease, the association disappeared. Thus, the high seroprevalence of HPV-16 among HIV-positive women may be explained by a high prevalence of HPV of all types. Approximately 50% of HIV-positive women had serological evidence of prior HPV-16 infection, but only approximately 5% had an HPV-16 cervical infection at baseline. Despite the higher prevalence of HPV infection in this group, most HIV-positive women are able to control HPV-16 replication at the cervix, and reactivation, if it occurs, is not very common.
Viscidi
Raphael P
RP
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. rviscid1@jhem.jhmi.edu
Ahdieh-Grant
Linda
L
Clayman
Barbara
B
Fox
Kelly
K
Massad
Leslie S
LS
Cu-Uvin
Susan
S
Shah
Keerti V
KV
Anastos
Kathryn M
KM
Squires
Kathleen E
KE
Duerr
Ann
A
Jamieson
Denise J
DJ
Burk
Robert D
RD
Klein
Robert S
RS
Minkoff
Howard
H
Palefsky
Joel
J
Strickler
Howard
H
Schuman
Paula
P
Piessens
Eva
E
Miotti
Paolo
P
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000276:immunology / Q000821:virology; D000328:Adult; D000914:Antibodies, Viral / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D016015:Logistic Models; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000150:complications* / Q000175:diagnosis / Q000276:immunology* / Q000821:virology; D012307:Risk Factors; D014412:Tumor Virus Infections / Q000150:complications / Q000175:diagnosis / Q000276:immunology / Q000821:virology; D014626:Vaginal Smears; D014775:Virus Activation
D000914:Antibodies, Viral; D007074:Immunoglobulin G